172 related articles for article (PubMed ID: 34554184)
1. A Middle Ground for Accelerated Drug Approval-Lessons From Aducanumab.
Emanuel EJ
JAMA; 2021 Oct; 326(14):1367-1368. PubMed ID: 34554184
[No Abstract] [Full Text] [Related]
2. Aducanumab and the Business of Alzheimer Disease-Some Choice.
Karlawish J
JAMA Neurol; 2021 Nov; 78(11):1303-1304. PubMed ID: 34410302
[No Abstract] [Full Text] [Related]
3. The Problem of Aducanumab for the Treatment of Alzheimer Disease.
Alexander GC; Karlawish J
Ann Intern Med; 2021 Sep; 174(9):1303-1304. PubMed ID: 34138642
[No Abstract] [Full Text] [Related]
4. Accelerated Approval of Aducanumab: Where Do We Stand Now?
Barenholtz Levy H
Ann Pharmacother; 2022 Jun; 56(6):736-739. PubMed ID: 34595939
[TBL] [Abstract][Full Text] [Related]
5. Revisiting FDA Approval of Aducanumab.
Alexander GC; Knopman DS; Emerson SS; Ovbiagele B; Kryscio RJ; Perlmutter JS; Kesselheim AS
N Engl J Med; 2021 Aug; 385(9):769-771. PubMed ID: 34320282
[No Abstract] [Full Text] [Related]
6. What the Aducanumab Approval Reveals About Alzheimer Disease Research.
Manly JJ; Glymour MM
JAMA Neurol; 2021 Nov; 78(11):1305-1306. PubMed ID: 34605885
[No Abstract] [Full Text] [Related]
7. Aducanumab and the FDA - where are we now?
Fillit H; Green A
Nat Rev Neurol; 2021 Mar; 17(3):129-130. PubMed ID: 33442064
[No Abstract] [Full Text] [Related]
8. [Aducanumab approval for Alzheimer's disease in the USA: the surrender of science].
Dal-Ré R
Rev Neurol; 2021 Oct; 73(8):296-297. PubMed ID: 34617583
[TBL] [Abstract][Full Text] [Related]
9. How the US Food and Drug Administration's approval of aducanumab for Alzheimer's disease has implication for oncology and beyond.
Lythgoe MP; Prasad V
Eur J Cancer; 2021 Nov; 157():68-70. PubMed ID: 34487987
[No Abstract] [Full Text] [Related]
10. Controversy and Progress in Alzheimer's Disease - FDA Approval of Aducanumab.
Rabinovici GD
N Engl J Med; 2021 Aug; 385(9):771-774. PubMed ID: 34320284
[No Abstract] [Full Text] [Related]
11. US Food and Drug Administration Approval of Aducanumab-Is Amyloid Load a Valid Surrogate End Point for Alzheimer Disease Clinical Trials?
Planche V; Villain N
JAMA Neurol; 2021 Nov; 78(11):1307-1308. PubMed ID: 34515750
[No Abstract] [Full Text] [Related]
12. Of education and public policy: Aducanumab.
Lundebjerg NE; Hollmann PA; Supiano MA
J Am Geriatr Soc; 2022 Jan; 70(1):81-84. PubMed ID: 34674219
[No Abstract] [Full Text] [Related]
13. Can we learn lessons from the FDA's approval of aducanumab?
Liu KY; Howard R
Nat Rev Neurol; 2021 Nov; 17(11):715-722. PubMed ID: 34535787
[TBL] [Abstract][Full Text] [Related]
14. The FDA Approves Aducanumab for Alzheimer's Disease, Raising Important Scientific Questions1.
de la Torre JC; Gonzalez-Lima F
J Alzheimers Dis; 2021; 82(3):881-882. PubMed ID: 34250943
[No Abstract] [Full Text] [Related]
15. Will CMS Find Aducanumab Reasonable and Necessary for Alzheimer Disease After FDA Approval?
Schulman KA; Greicius MD; Richman B
JAMA; 2021 Aug; 326(5):383-384. PubMed ID: 34279572
[No Abstract] [Full Text] [Related]
16. The approval of Aduhelm risks eroding public trust in Alzheimer research and the FDA.
Karlawish J; Grill JD
Nat Rev Neurol; 2021 Sep; 17(9):523-524. PubMed ID: 34267383
[No Abstract] [Full Text] [Related]
17. Controversial Approval of New Drug to Treat Alzheimer's Disease.
Aschenbrenner DS
Am J Nurs; 2021 Oct; 121(10):22-23. PubMed ID: 34554982
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of Aducanumab for Alzheimer Disease: Scientific Evidence and Regulatory Review Involving Efficacy, Safety, and Futility.
Alexander GC; Emerson S; Kesselheim AS
JAMA; 2021 May; 325(17):1717-1718. PubMed ID: 33783469
[No Abstract] [Full Text] [Related]
19. Update: FDA approval of Biogen's aducanumab.
Hollmann P
Geriatr Nurs; 2022; 43():318-319. PubMed ID: 34996638
[No Abstract] [Full Text] [Related]
20. What to Know About the Alzheimer Drug Aducanumab (Aduhelm).
Woloshin S; Kesselheim AS
JAMA Intern Med; 2022 Aug; 182(8):892. PubMed ID: 35666531
[No Abstract] [Full Text] [Related]
[Next] [New Search]
